Glaxosmithkline Share News (GSK)

UPDATE 2-Novartis launches chronic disease programme for poor countries

* Scheme initially targets Kenya, Ethiopia, Vietnam * Treatments for hypertension, diabetes, breast cancer * Company plans eventually to roll out to 30 countries (Adds details on cost of medicines, spike in diabetes cases in Vietnam) By John Miller ZURICH, Sept 24 (Reute

GlaxoSmithKline to file application for COPD drug in Japan

(ShareCast News) - GlaxoSmithKline and Theravance intend to file a supplemental new drug application with the Japanese regulatory authority in the first quarter of 2016 for Relvar Ellipta, which is used for the treatment of chronic obstructive pulmonary disease. The pharmaceuticals company said the

GlaxoSmithKline Plans Filing Of Relvar Ellipta In Japan For COPD

GSK may get EU green light for new biotech asthma drug this week

* Nucala is first in new drug class for severe asthma * EMA weighs verdict on Nucala at Sept. 21-24 meeting By Ben Hirschler LONDON, Sept 23 (Reuters) - GlaxoSmithKline may get a green light from European regulators as early as this week for a new biotech medicine to treat sever

Hillary Clinton Outlines Plans To Stop Drug Industry "Price Gouging"

GlaxoSmithKline's ViiV Says Triumeq Study Meets Primary Endpoint

LONDON MARKET CLOSE: Commodities And Pharma Push FTSE 100 Below 6,000

LONDON MARKET MIDDAY: Miners, Drug Makers And VW Drive FTSE 100 Lower

LONDON MARKET OPEN: Drug Stocks Hit By Clinton Price-Gouging Tweet

LONDON BRIEFING: Miners And Drug Stocks Hit By Downgrades And A Tweet

Roche shows its intent with Switzerland's tallest skyscraper

By John Miller BASEL, Sept 18 (Reuters) - Visible from neighbouring France and Germany, a new 41-storey skyscraper that drugs company Roche opened near the river Rhine on Friday reaches 178 meters into the sky, easily the tallest building in Switzerland. The 550-million Swiss franc (

Avacta Snaps Up GlaxoSmithKline Alumni As Non-Executive

Analysis of GSK's Seroxat antidepressant finds key data was held back

By Kate Kelland LONDON, Sept 17 (Reuters) - A medical journal criticised British drugmaker GlaxoSmithKline on Thursday for delaying access to key data from a trial of its antidepressant Seroxat that would have shown earlier that it is neither safe or effective in adolescents. The wide

BROKER RATINGS SUMMARY: Exane BNP In Double Upgrade Of Reckitt

LONDON BRIEFING: Glencore Shares Rise After Successful Placing